Drug Trial Radar · NCT07622329
A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Sep 2, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- The General Hospital of Western Theater CommandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, recommended subsequent dose, pharmacokinetic profile, and preliminary efficacy of JCXH-213 in adult patients with primary immune thrombocytopenia (ITP) who are refractory or relapsed after treatment with corticosteroids and second-line therapies. The study consists of a screening period, treatment period, end-of-treatment visit, safety follow-up, and study withdrawal visit. Two dose groups are planned: 2 mg and 4 mg, with 2 patients to be enrolled in each dose group. During the treatment period, JCXH-213 at the assigned dose will be administered once every other day for a total of 7 doses. Assessments for safety and efficacy will be conducted according to the study schedule. After the last dose, patients will undergo an end-of-treatment visit and safety follow-up until the end of the study.
Conditions
- Thrombocytopenic Purpura, Immune
Interventions
JCXH-213Drug
An mRNA-LNP based in vivo CAR therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of JCXH-213Time frame: The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Hospital of Western Theater Command of PLA
Chengdu, Chengdu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.